AZN: Full-Year 2017 Results

AstraZeneca PLC

2 February 2018 07:00

Full-Year 2017 Results

Encouraging progress made on commercial execution and cost discipline; Product Sales growth in the quarter.

AstraZeneca positioned for Product Sales growth from FY 2018

Please see attached PDF to view the announcement in full.

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links